These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19549711)

  • 1. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.
    Linderholm BK; Hellborg H; Johansson U; Elmberger G; Skoog L; Lehtiö J; Lewensohn R
    Ann Oncol; 2009 Oct; 20(10):1639-46. PubMed ID: 19549711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.
    Uhm JE; Park YH; Yi SY; Cho EY; Choi YL; Lee SJ; Park MJ; Lee SH; Jun HJ; Ahn JS; Kang WK; Park K; Im YH
    Int J Cancer; 2009 Mar; 124(6):1457-62. PubMed ID: 19065658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
    Li J; Liu X; Tong Z
    Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
    Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
    Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy.
    Yehia L; Boulos F; Jabbour M; Mahfoud Z; Fakhruddin N; El-Sabban M
    PLoS One; 2015; 10(6):e0129356. PubMed ID: 26046764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
    Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
    Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer.
    Taha FM; Zeeneldin AA; Helal AM; Gaber AA; Sallam YA; Ramadan H; Moneer MM
    Clin Biochem; 2009 Sep; 42(13-14):1420-6. PubMed ID: 19576877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.
    Sanchez BC; Sundqvist M; Fohlin H; Spyratos F; Nordenskjöld B; Stål O; Linderholm BK
    Eur J Cancer; 2010 Jun; 46(9):1580-7. PubMed ID: 20413297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
    Gasparini G; Toi M; Gion M; Verderio P; Dittadi R; Hanatani M; Matsubara I; Vinante O; Bonoldi E; Boracchi P; Gatti C; Suzuki H; Tominaga T
    J Natl Cancer Inst; 1997 Jan; 89(2):139-47. PubMed ID: 8998183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative breast cancer survival in Iranian patients.
    Aghili M; Lashkari M; Farrokhpey AH; Izadi S
    Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
    Bahhnassy A; Mohanad M; Shaarawy S; Ismail MF; El-Bastawisy A; Ashmawy AM; Zekri AR
    Mol Med Rep; 2015 Jul; 12(1):851-64. PubMed ID: 25824321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India.
    ; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP
    Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
    Ma JG; Wang NJ; Yu WJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vimentin as a poor prognostic factor for triple-negative breast cancer.
    Yamashita N; Tokunaga E; Kitao H; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Aishima S; Morita M; Maehara Y
    J Cancer Res Clin Oncol; 2013 May; 139(5):739-46. PubMed ID: 23354842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.